Koers Pieris Pharmaceuticals Inc OTC Bulletin Board
Aandelen
PIRS
US7207951036
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- | - |
Omzet 2022 | 25,9 mln. 0 23,88 mln. | Omzet 2023 | 42,81 mln. 0 39,47 mln. | Marktkapitalisatie | 17,99 mln. 0 16,59 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -33 mln. - -30,43 mln. | Nettowinst (verlies) 2023 | -24 mln. - -22,13 mln. | EV/omzet 2022 | 1,21 x |
Nettoliquiditeiten 2022 | 46,07 mln. 0 42,48 mln. | Nettoliquiditeiten 2023 | 26,37 mln. 0 24,31 mln. | EV/omzet 2023 | -0,2 x |
K/w-verhouding 2022 |
-2,32
x | K/w-verhouding 2023 |
-0,67
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 93,03% |
Recentste transcriptie over Pieris Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 01-01-10 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 01-12-17 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 59 | 20-09-16 | |
James Geraghty
CHM | Chairman | 69 | 22-05-17 |
Michael Richman
BRD | Director/Board Member | 63 | 17-12-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. |
- Beurs
- Aandelen
- Koers PIRS
- Koers PIRS